$PRE

AM Best reports that a group of U.S. and Bermuda reinsurers maintained underwriting profitability in 2025, with a 16.8% net return on equity, despite slower premium growth. The composite includes seven companies, such as Arch Capital and Everest Group. Profitability was supported by higher investment income, but growth slowed to less than 1.0% due to market softening. AM Best expects muted growth in 2026 amid declining rates in property and casualty lines.

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

Rosin Brian J (CFO of IM8 (US) LLC) purchased 23,100 shares of Prenetics Global Ltd (PRE) at an average of $21.55 ($21.19–$22.80, $0.50M total) across 2 trades over 2026-08-24 to 2026-08-25.

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

Benchmark initiated coverage of Prenetics Global Ltd (PRE) with a Buy rating and a $30 price target, citing growth in the supplement market. Insider transactions were also reported.

Yeung Danny Sheng Wu (Chief Executive Officer) purchased 24,681 shares of Prenetics Global Ltd (PRE) at an average of $20.34 ($18.31–$21.40, $0.50M total) across 3 trades over 2026-08-20 to 2026-08-24.

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.

Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.

Alliance News RNS hotlist covers UK politics and multiple AIM-listed company updates. ValiRx (VAL) says Cytolytix’s European patent application is set to be granted. Tertiary Minerals (TYM) reports Phase 4 drilling completion and preliminary pXRF results at Mushima North. Thruvision (THRU) expects over £3m revenue from airport deployments. Other items include STG £3m DRIVE35 grant, XTR Morocco project works, and KEN pXRF LREO grades.

Alliance News says London stocks may open marginally higher as investors watch Strait of Hormuz talks and corporate earnings. Iran and Oman agreed a route and are finalizing joint management, but reopening depends on the US ending Iran port naval blockade. Company updates include WNX selling “Pain Away” to Mentholatum, Corero (CNS) revenue up 42% to $15.5m, PRE receiving $15m of a $165m investment, and TEK reporting H1 net assets $201.7m and profit after tax $144.8m.